{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:06:07Z","timestamp":1790802367243,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ejca.2026.117045","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T23:25:07Z","timestamp":1789169107000},"page":"117045","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Quality of life in patients with RAS wild-type metastatic colorectal cancer treated mFOLFOXIRI\u202f+\u202fpanitumumab versus FOLFOXIRI: A prespecified secondary analysis of the phase II VOLFI AIO-KRK 0109 trial"],"prefix":"10.1016","volume":"247","author":[{"given":"Tshilidzi M.","family":"Klingler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe M.","family":"Martens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Riera-Knorrenschild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swen","family":"Wessendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Ettrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Kanzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Lugani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8381-105X","authenticated-orcid":false,"given":"Elena","family":"Rohleder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1041-0137","authenticated-orcid":false,"given":"Arndt","family":"Stahler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9798-3319","authenticated-orcid":false,"given":"Alena A.","family":"Hasenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swantje","family":"Held","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Buechner-Steudel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Atzpodien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Heinemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Geissler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik P.","family":"Modest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3895-5879","authenticated-orcid":false,"given":"Johannes","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2026.117045_bib1","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0140-6736(24)00360-X","article-title":"Colorectal cancer","volume":"404","author":"Eng","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2026.117045_bib2","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1200\/JCO.22.01690","article-title":"Treatment of Metastatic Colorectal Cancer: ASCO Guideline","volume":"41","author":"Morris","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.117045_bib3","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.annonc.2026.03.005","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up\u2606","volume":"37","author":"Cremolini","year":"2026","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.117045_bib4","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/S1470-2045(16)30269-8","article-title":"FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial","volume":"17","author":"Stintzing","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.117045_bib5","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1200\/JCO.2018.78.3183","article-title":"Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: the Open-Label, Randomized, Phase III TAILOR Trial","volume":"36","author":"Qin","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.117045_bib6","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1001\/jama.2023.4428","article-title":"Panitumumab vs Bevacizumab added to standard first-line chemotherapy and overall survival among patients with RAS wild-type, left-sided metastatic colorectal cancer: a randomized clinical trial","volume":"329","author":"Watanabe","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.ejca.2026.117045_bib7","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.33533","article-title":"Maintenance therapy with cetuximab after FOLFIRI Plus Cetuximab for RAS wild-type metastatic colorectal cancer: a phase 2 randomized clinical trial","volume":"6","author":"Boige","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ejca.2026.117045_bib8","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1200\/JCO.21.01332","article-title":"Panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS Wild-Type metastatic colorectal cancer: the randomized PANAMA Trial (AIO KRK 0212)","volume":"40","author":"Modest","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.117045_bib9","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","article-title":"ESMO consensus guidelines for the management of patients with metastatic colorectal cancer","volume":"27","author":"Van Cutsem","year":"2016","journal-title":"Ann Oncol J Eur Soc Med Oncol"},{"key":"10.1016\/j.ejca.2026.117045_bib10","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1200\/JCO-25-01337","article-title":"Upfront Modified FOLFOXIRI Plus Panitumumab for RAS\/BRAF wild-type metastatic colorectal cancer: final results of the phase III TRIPLETE Study","volume":"44","author":"Conca","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.117045_bib11","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1200\/JCO.19.01340","article-title":"FOLFOXIRI plus panitumumab as first-line treatment of RAS wild-type metastatic colorectal cancer: the randomized, open-label, Phase II VOLFI Study (AIO KRK0109)","volume":"37","author":"Modest","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.117045_bib12","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.critrevonc.2015.06.001","article-title":"Acute skin toxicity management in head and neck cancer patients treated with radiotherapy and chemotherapy or EGFR inhibitors: literature review and consensus","volume":"96","author":"Russi","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ejca.2026.117045_bib13","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1002\/cam4.1623","article-title":"A prospective Phase II study to examine the relationship between quality of life and adverse events of first-line chemotherapy plus cetuximab in patients with KRAS wild-type unresectable metastatic colorectal cancer: QUACK trial","volume":"7","author":"Iwamoto","year":"2018","journal-title":"Cancer Med"},{"key":"10.1016\/j.ejca.2026.117045_bib14","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1038\/bjc.2011.409","article-title":"Health-related quality of life in patients with metastatic colorectal cancer treated with panitumumab in first- or second-line treatment","volume":"105","author":"Bennett","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2026.117045_bib15","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.ejca.2026.117045_bib16","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.1016\/S0959-8049(01)00448-8","article-title":"EORTC Quality of Life Group & Quality of Life Unit. Quality of life research within the EORTC-the EORTC QLQ-C30. European Organisation for Research and Treatment of Cancer","volume":"38","author":"Fayers","year":"2002","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.117045_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2026.116694","article-title":"Sex differences in efficacy and toxicity of first-line treatment of metastatic colorectal cancer: an analysis of 18,041 patients in the ARCAD CRC database","volume":"238","author":"Wagner","year":"2026","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.117045_bib18","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ejca.2012.08.023","article-title":"Quality of life analysis in patients with KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin","volume":"49","author":"L\u00e1ng","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.117045_bib19","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1634\/theoncologist.2008-0003","article-title":"Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer","volume":"13","author":"Kabbinavar","year":"2008","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2026.117045_bib20","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1634\/theoncologist.8-4-342","article-title":"Health-related quality of life in female long-term colorectal cancer survivors","volume":"8","author":"Trentham-Dietz","year":"2003","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2026.117045_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.112955","article-title":"Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab as maintenance therapy: a prespecified secondary analysis of the PanaMa (AIO KRK 0212) trial","volume":"190","author":"Ballhausen","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.117045_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103628","volume":"9","author":"Ballhausen","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2026.117045_bib23","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00432-017-2534-z","article-title":"Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in three randomised panitumumab trials","volume":"144","author":"Taieb","year":"2018","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ejca.2026.117045_bib24","first-page":"e29","article-title":"Quality of Life Analysis in Patients With RAS wild-type metastatic colorectal cancer treated with first-line cetuximab plus chemotherapy","volume":"16","author":"Yamaguchi","year":"2017","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.ejca.2026.117045_bib25","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1186\/1471-2407-12-438","article-title":"Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study","volume":"12","author":"Thaler","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2026.117045_bib26","first-page":"329","article-title":"Psychological effects of cetuximab-induced cutaneous rash in advanced colorectal cancer patients","volume":"18","author":"Romito","year":"2010","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ejca.2026.117045_bib27","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926008269?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926008269?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:34:18Z","timestamp":1790800458000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926008269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":27,"alternative-id":["S0959804926008269"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.117045","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quality of life in patients with RAS wild-type metastatic colorectal cancer treated mFOLFOXIRI\u202f+\u202fpanitumumab versus FOLFOXIRI: A prespecified secondary analysis of the phase II VOLFI AIO-KRK 0109 trial","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.117045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"117045"}}